Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ CKPT opened at $3.39 on Monday. Checkpoint Therapeutics has a 1-year low of $1.36 and a 1-year high of $4.50. The firm has a market capitalization of $165.53 million, a PE ratio of -1.84 and a beta of 1.34. The business’s fifty day moving average price is $3.50 and its two-hundred day moving average price is $2.67.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Equities research analysts expect that Checkpoint Therapeutics will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several large investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in Checkpoint Therapeutics during the third quarter valued at approximately $30,000. XTX Topco Ltd acquired a new position in shares of Checkpoint Therapeutics in the 2nd quarter valued at approximately $34,000. Gladstone Institutional Advisory LLC raised its stake in shares of Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 20,500 shares during the period. Magnus Financial Group LLC raised its holdings in shares of Checkpoint Therapeutics by 12.9% in the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Choreo LLC raised its holdings in Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after acquiring an additional 7,080 shares in the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.